For The Better

Growth stocks with wide moats and strong financials can compound investor returns with time.

Down big to start 2024, these two businesses still look way too promising to sell. One may even be a screaming buy.

Does Bristol Myers have the potential to be a market-beating stock?

Block stock is on the outs with investors. Does that spell opportunity?

Cost-cutting measures and improving end markets gave investors cause for optimism this week.

Will a less favorable outcome on swipe fees hurt the stocks long-term?

Not all stocks are at all-time highs. Here are three excellent businesses trading for a discount right now.

The world’s top digital asset has soared in the past year and a half.

The hype related to Nvidia’s stake in the company appears to have faded. Is it time to start looking for SoundHound AI stock to rebound?

Agree Realty is a growing net lease REIT with plenty of runway for expansion ahead. And it has an attractive dividend yield.

The company could become a prominent player in the biotech industry, but that might take a while.

Palantir might look overvalued, but it stands in a unique position.

The stocks offers a hefty 6% dividend yield and is trading near decade lows.

Looking for Buffett bargains? These two stock picks are for you.

This upcoming marriage speaks volumes about the Buy Now, Pay Later industry.

The GPU leader’s huge success opens it up to the risk of a regulatory crackdown.

Rivian’s R1S was one of the biggest gainers in registrations year over year — here’s how the top 10 looks.

This contract electronics manufacturer has underperformed on the stock market in 2024, but there may be a chance of a turnaround.

These healthcare stocks have clear paths to growth over the next few years.

If contributing to a retirement plan gives you anxiety, consider this often-overlooked feature.